Blood Preparation Market size projected to grow at around 4% CAGR between 2016 and 2023

Blood Preparation Market size was valued at USD 45 billion in 2015 and is projected to grow at around 4% CAGR between 2016 and 2023. Whole blood preparation market share accounted for over 45% of the global revenue in 2015. 

Growing demand for blood transfusion and other components owing to the rising number of patients in emergency departments is forecast to drive growth. Increase in occurrence of disorders such as thrombocytosis globally along with a requirement of blood during surgical procedures, accidents and treatment of diseases are also major industry drivers. As per a report by the Centers for Disease Control and Prevention (CDC), 60,000 to 100,000 Americans die on account of DVT/PE per year in the U.S. and approximately two people out of 1,000 are affected by the disease. Initiatives taken by organizations like the CDC and National Institutes of Health (NIH) for spreading awareness against prevention of thrombosis-associated complications in early stages will further increase the demand in the near future. 

The development of high speed and efficient technology for separation of blood components without losing their activity will drive growth. Key drugs such as Urokinase being relaunched in the North American region, launch of new oral anti-coagulants and commercialization of new drugs, growing geriatric population and increasing healthcare expenditures along with considerable untapped opportunities will also fuel blood preparation market growth.

Request for an in-depth table of contents for this report @ https://www.gminsights.com/request-toc/upcoming/468

The demand for source plasma by pharmaceutical industries for producing various plasma derived therapeutics is on the rise. In addition, the need for specific products such as packed red cells for treating cardiovascular patients, leukocyte reduced RBC for patients having alloimmunity towards various RBC has opened up new possibilities. 

Risk of acquiring blood transmitted diseases such as HIV, Hepatitis B, viral hemorrhagic fevers and attempts at developing substitutes are major restraining factors. 

The global blood preparation market is divided into various segments based on product, anti-coagulant and anti-thrombotics types and their applications. North America was the largest regional segment and was estimated at over USD 24 billion in 2015. Asia Pacific blood preparation market share is estimated to exhibit the fastest growth rate till 2023, driven by positive government initiatives, growing healthcare infrastructure in Australia and Japan, and untapped growth potential in densely populated countries such as India and China. 

On the basis of type of product, the industry is categorized into whole blood (comprising of granulocytes, red cells, and plasma and platelets) and blood components (comprising of packed red cells, whole blood components, frozen plasma, leukocyte reduced RBC, and platelet concentrate). 

Based on the anti-coagulant and anti-thrombotics type, the blood preparation market is divided into platelet aggregation inhibitors (COX inhibitors, glycoprotein inhibitors, phosphodiesterase inhibitors, and ADP antagonists), fibrinolytics (urokinase, tissue plasminogen activator, streptokinase), and anticoagulants (low molecular weight, unfractionated, and ultra low molecular weight heparins, vitamin K antagonists, direct factor Xa inhibitors, and direct thrombin inhibitors). 

Key application segments include thrombocytosis, pulmonary embolism, and renal impairment. Due to the rapid increasing spread of thrombosis related disorders, rise in geriatric population and increasing need for quick and effective drugs, anti-coagulants dominated the anti-coagulant and anti-thrombotics sector. Further, the awareness being created by the increasing government initiatives to prevent thrombosis and other related disorders will favorably impact revenue. 

The direct factor Xa inhibitor market comprising of newly introduced oral products such as Eliquis, Savayasa and Xarelto is projected to witness high growth in the coming years. 

Major players inthe blood preparation market include pharma companies such as Pfizer Inc., GlaxoSmithKline PLC, Leo Pharma Inc., Sanofi Aventis, Celgene Corp, Baxter Healthcare Corp., Bristol-Myers Squibb Co., Shandong East Chemical Industry Co. and AstraZeneca Co. Being a technology driven industry, companies invest heavily in R&D to develop new, cost effective and efficient drugs for the treatment of various disorders.